Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine

Adenovirus vectored vaccines are a highly effective strategy to induce cellular immune responses which are particularly effective against intracellular pathogens. Recombinant simian adenovirus vectors were developed to circumvent the limitations imposed by the use of human adenoviruses due to widesp...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän:	Folegatti, P, Bellamy, D, Roberts, R, Powlson, J, Edwards, N, Mair, C, Bowyer, G, Poulton, I, Mitton, C, Green, N, Berrie, E, Lawrie, A, Hill, A, Ewer, K, Hermon-Taylor, J, Gilbert, S
Materialtyp:	Journal article
Publicerad:	MDPI 2019

Liknande verk

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
av: Pedro M. Folegatti, et al.
Publicerad: (2019-05-01)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
av: Zhang, C, et al.
Publicerad: (2023)

CMV-associated T cell and NK cell terminal differentiation does not impact immunogenicity of ChAdOx1 vaccination
av: Sharpe, HR, et al.
Publicerad: (2022)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
av: Cheng Zhang, et al.
Publicerad: (2023-06-01)

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
av: Adam Berg, et al.
Publicerad: (2021-10-01)

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
av: Hannah R. Sharpe, et al.
Publicerad: (2022-03-01)

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza a antigens
av: Antrobus, R, et al.
Publicerad: (2014)

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.
av: Antrobus, R, et al.
Publicerad: (2014)

Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity
av: Jinnam Kim, et al.
Publicerad: (2023-04-01)

Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens
av: Moreira Folegatti, P
Publicerad: (2021)

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
av: O'Hara, G, et al.
Publicerad: (2012)

A single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial
av: Folegatti, P, et al.
Publicerad: (2021)

Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa
av: Ashley C. Beavis, et al.
Publicerad: (2023-07-01)

Safety and immunogenicity of adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies
av: Folegatti, P, et al.
Publicerad: (2021)

Safety and immunogenicity of ChAdOx1 MERS Vaccine Candidate in Healthy Middle Eastern Adults: a dose-escalation, open-label, non-randomised, phase 1b trial
av: Bosaeed, M, et al.
Publicerad: (2021)

Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV
av: Charlotte Davis, et al.
Publicerad: (2024-06-01)

Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice
av: Dicks, M, et al.
Publicerad: (2015)

Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine
av: Edmund G.-T. Wee, et al.
Publicerad: (2024-08-01)

Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies
av: Pedro M. Folegatti, et al.
Publicerad: (2021-03-01)

Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels
av: Alharbi, N, et al.
Publicerad: (2019)

Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan
av: Jer-Hwa Chang, et al.
Publicerad: (2022-02-01)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
av: Hermosilla, E, et al.
Publicerad: (2022)

Safety and immunogenicity of a replication deficient simian adenoviral vectored chikungunya vaccine: A phase I, first-in-human, dose escalation trial
av: Folegatti, PM, et al.
Publicerad: (2019)

Association of Reactogenicity with Immunogenicity of the ChAdOx1 nCoV-19 Vaccine in Patients Undergoing Hemodialysis
av: Ting-Yun Lin, et al.
Publicerad: (2022-08-01)

HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV
av: Tamsin Cargill, et al.
Publicerad: (2023-11-01)

Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population
av: Nawamin Pinpathomrat, et al.
Publicerad: (2022-05-01)

Durability of ChAdOx1 nCov-19 vaccination in people living with HIV
av: Ogbe, A, et al.
Publicerad: (2022)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
av: Eduardo Hermosilla, et al.
Publicerad: (2022-03-01)

Immunogenicity and efficacy of Zika virus envelope domain III in DNA, protein, and ChAdOx1 adenoviral-vectored vaccines
av: López-Camacho, C, et al.
Publicerad: (2020)

Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines
av: César López-Camacho, et al.
Publicerad: (2020-06-01)

Is the ChAdOx1 Vaccine Safe and Immunogenic as Prophylactic Measure Against the Lethal Human-Coronaviruses? A Systematic Review
av: Andréia Michelle Alves Cunha de Alcântar, et al.
Publicerad: (2023-07-01)

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
av: Ane Ogbe, et al.
Publicerad: (2022-04-01)

Simian adenoviruses as vaccine vectors
av: Morris, S, et al.
Publicerad: (2016)

Simian adenoviruses as vaccine vectors
av: Morris, S, et al.
Publicerad: (2016)

Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand
av: Kriangkrai Chawansuntati, et al.
Publicerad: (2024-06-01)

Impact of ChAdOx1 or DNA Prime Vaccination on Magnitude, Breadth, and Focus of MVA-Boosted Immunogen-Specific T Cell Responses
av: Alex Olvera, et al.
Publicerad: (2024-03-01)

Author Correction: Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population
av: Nawamin Pinpathomrat, et al.
Publicerad: (2022-09-01)

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured onthe AGE1.CR.pIX Avian Cell Line
av: Folegatti, P, et al.
Publicerad: (2019)

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
av: Folegatti, PM, et al.
Publicerad: (2020)

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
av: Barrett, J, et al.
Publicerad: (2020)